Ion Beam Applications SA (EBR:IBAB)
Belgium flag Belgium · Delayed Price · Currency is EUR
12.02
+0.14 (1.18%)
Jul 18, 2025, 5:35 PM CET

Ion Beam Applications Company Description

Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments in Belgium, the United States, and internationally.

It operates through Proton Therapy and Other Accelerators; and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems.

This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization.

The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures.

The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer.

It also develops ConformalFLASH, a novel technique using the proton Bragg peak. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Ion Beam Applications SA
Ion Beam Applications logo
CountryBelgium
Founded1986
IndustryMedical Devices
SectorHealthcare
Employees2,287
CEOOlivier Legrain

Contact Details

Address:
3, Chemin du Cyclotron
Louvain-la-Neuve, 1348
Belgium
Phone32 1 047 58 11
Websiteiba-worldwide.com

Stock Details

Ticker SymbolIBAB
ExchangeEuronext Brussels
Fiscal YearJanuary - December
Reporting CurrencyEUR
ISIN NumberBE0003766806
SIC Code3845

Key Executives

NamePosition
Henri de RomreeDeputy Chief Executive Officer
Olivier LegrainChief Executive Officer, MD and Executive Director
Pierre MottetChairman of the Board
Yves JongenFounder, Chief Research Officer, MD and Executive Director
Olivier LechienCorporate Communication Director
Thomas CanonSustainability Program Director
Bruno ScutnairePresident of IBA RadioPharma Solutions